Before weighing new options, the panel resets the foundation: how antiretroviral classes work, what the 2026 DHHS update actually changed, and why therapy should start as soon as possible.
Key Updates in the HIV Treatment Landscape
Integrase inhibitors remain the clear first choice, yet prior long-acting PrEP exposure and the practical realities of same-day starts are reshaping when alternatives make more sense.
As people with HIV live longer, first-line decisions increasingly hinge on cardiovascular risk, comorbidities, and drug interactions — areas where the pharmacist's full view of the medication list matters most.
One molecule now carries both a prevention and a treatment indication, and the panel outlines how pharmacists serve as the critical checkpoint against dispensing errors and inadvertent monotherapy.
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Pneumococcal Vaccines Show Moderate Immunogenicity, Strong Safety in Children With Cancer
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5